Get the Stockscreener App
4.36
1.87%
0.08
After Hours:
4.60
0.24
+5.50%
Grace Therapeutics Inc stock is traded at $4.36, with a volume of 1.08M.
It is up +1.87% in the last 24 hours and up +3.81% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$4.28
Open:
$4.3
24h Volume:
1.08M
Relative Volume:
2.57
Market Cap:
$67.47M
Revenue:
-
Net Income/Loss:
$-5.98M
P/E Ratio:
-12.10
EPS:
-0.3603
Net Cash Flow:
$-9.83M
1W Performance:
+22.13%
1M Performance:
+3.81%
6M Performance:
+40.06%
1Y Performance:
+101.85%
1-Day Range:
$4.29
$4.75
1-Week Range:
$3.445
$4.75
52-Week Range:
$2.00
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
4.36 | 66.23M | 0 | -5.98M | -9.83M | -0.3603 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Grace Therapeutics to present GTx-104 trial data at neurology meeting - Investing.com India
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 - The Manila Times
Grace lands AAN 2026 poster slot for Phase 3 GTx-104 trial - Stock Titan
Merger Talk: Can Grace Therapeutics Inc weather a recessionTrade Risk Summary & Entry Point Confirmation Signals - baoquankhu1.vn
Grace Therapeutics, Inc.'s (NASDAQ:GRCE) Path To Profitability - simplywall.st
GRCE Options Chain — NASDAQ:GRCE - TradingView — Track All Markets
GRCE Technical Analysis & Stock Price Forecast - Intellectia AI
Grace Therapeutics Inc. Live Share Prices and Trades. GRCE.US Live Streaming Share Prices. - London South East
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Published on: 2026-04-07 03:54:45 - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - Yahoo Finance
INO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Replimune, Grace among biotechs with April PDUFA dates - BioCentury
GRCE Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Bull Run: Does MITK align with a passive investing strategy2026 Historical Comparison & Daily Chart Pattern Signals - baoquankhu1.vn
HOTH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
What is Grace Therapeutics Incs valuation compared to sectorJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - intellectia.ai
CELZ Technical Analysis & Price Forecast - Intellectia AI
VUZI Technical Analysis & Price Forecast - Intellectia AI
ZYXI Technical Analysis & Price Forecast - Intellectia AI
Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8% - MarketBeat
Analyst Upgrade: How much upside does New Fortress Energy Inc haveWeekly Investment Recap & Low Risk Entry Point Tips - baoquankhu1.vn
DG Technical Analysis & Price Forecast - intellectia.ai
PUGBY News & Events - Intellectia AI
If You Invested $1,000 in Grace Therapeutics, Inc (GRCE) - Stock Titan
BRX Technical Analysis & Price Forecast - intellectia.ai
EVSB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
EVSB PE Ratio & Valuation, Is EVSB Overvalued - Intellectia AI
AHH Technical Analysis & Price Forecast - intellectia.ai
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GARP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
FIBK Technical Analysis & Price Forecast - intellectia.ai
NAT Technical Analysis & Price Forecast - Intellectia AI
DALN Technical Analysis & Price Forecast - Intellectia AI
WASH.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Returns Recap: Can Grace Therapeutics Inc maintain sales growth2026 Trade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why is Grace Therapeutics Inc stock going up2026 Momentum Check & AI Powered Market Entry Ideas - baoquankhu1.vn
HLIT Technical Analysis & Price Forecast - Intellectia AI
IXHL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences - The Manila Times
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - The Manila Times
Why some brain bleed patients miss full doses takes center stage at 2 meetings - Stock Titan
RGNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Revenue of Grace Therapeutics, Inc. from 2020 to 2021 - Statista
Market Trends: Is KIMPRN a play on infrastructure spending2026 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):